CNBC'S Catherine Boyle Doesn't Think A Pfizer/AstraZeneca Deal Will Happen Soon

Pfizer Inc. PFE has been courting AstraZeneca plc (ADR) AZN for long.

CNBC's Catherine Boyle, who has been following this deal, recently reported on the current status of the deal.

“What it seems it looks like the possibilities of it [the deal] have definitely receded," Boyle said. "It is very difficult for anyone close to Pfizer to comment on it because frankly they are all petrified of the takeover panel here in the UK, which came down on them pretty heavily last time. So, I think it might look that there are still some rationale for Pfizer to go to after AstraZeneca."

"We don't actually have much clarity. While there has been some rules in tax inversions, we don’t actually know what those laws are likely to be, what those regulations are likely to be […] and also there is still the rationale of a good pipeline that Pfizer is looking at and they do still have plenty of offshore cash and they need something to do with it."

When asked about AstraZeneca’s need to increase revenues, Boyle said, "they have set some pretty really really ambitious revenue targets. I think, certainly they have been quite lucky this year because their generic competition for Nexium, which is their heartburn drug, hasn’t come through as quickly as expected, but I think potentially if you see any kind of disappointment next year, maybe even in 2016, any signs they are not going to hit at that key target of getting back to 2013 revenues."

Shares of Pfizer recently traded at $30.95, up 1.5 percent.